Can FDA Finally Put Its Zohydro Problem Behind It?
FDA sees progress on the opioid front with Zogenix and Teva the latest to seek abuse-deterrence claims, but is the existing science able to adequately fight abuse?
You may also be interested in...
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
From surprisingly contentious to surprisingly unanimous, VRBPAC's favorable votes have grown from 17 to 21 over the course of three meetings on coronavirus vaccines.